Get the Stockscreener App
37.02
0.59%
-0.22
Pre-market:
37.23
0.21
+0.57%
Cogent Biosciences Inc stock is traded at $37.02, with a volume of 1.36M.
It is down -0.59% in the last 24 hours and up +0.46% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$37.24
Open:
$37.54
24h Volume:
1.36M
Relative Volume:
0.63
Market Cap:
$6.01B
Revenue:
-
Net Income/Loss:
$-328.94M
P/E Ratio:
-15.12
EPS:
-2.4487
Net Cash Flow:
$-266.00M
1W Performance:
-7.38%
1M Performance:
+0.46%
6M Performance:
+186.09%
1Y Performance:
+416.32%
1-Day Range:
$36.65
$38.20
1-Week Range:
$36.40
$40.12
52-Week Range:
$3.72
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
37.02 | 6.04B | 0 | -328.94M | -266.00M | -2.4487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-10-25 | Upgrade | Stifel | Hold → Buy |
| Nov-10-25 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-16-25 | Initiated | Stifel | Hold |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
Rafferty Asset Management LLC Purchases 57,139 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences slips after upsized $200 mln equity offering - TradingView
Cogent Biosciences: Trio Of Approvals Beckon For Lead DrugStill Bullish (NASDAQ:COGT) - Seeking Alpha
A Look At Cogent Biosciences (COGT) Valuation After Recent Share Price Volatility - Yahoo Finance
Bezuclastinib SUMMIT Data Reframe Cogent Biosciences Mastocytosis Opportunity - Yahoo Finance
Cogent Biosciences (COGT) Reveals Promising Results in Latest Be - GuruFocus
Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval - Insider Monkey
Price-Driven Insight from (COGT) for Rule-Based Strategy - Stock Traders Daily
Cogent Biosciences Reports Promising 48-Week Results for Bezuclastinib in NonAdvanced Systemic Mastocytosis Patients - Quiver Quantitative
Cogent Biosciences Highlights Additional Data with Six - GlobeNewswire
A Look At Cogent Biosciences (COGT) Valuation After A Strong One Year Shareholder Return - Sahm
Cogent Biosciences, Inc. (COGT) - DirectorsTalk Interviews
Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval - Yahoo Finance
How Do Cogent Biosciences’ Growing Losses and ESOP Shelf Shape Its Capital Strategy Narrative (COGT)? - simplywall.st
COGT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cogent Biosciences Balances Bezuclastinib Phase 3 Progress With Dilution Risk - Sahm
Cogent Biosciences, Inc. $COGT Stock Position Cut by NEOS Investment Management LLC - MarketBeat
Cogent Biosciences, Inc. (COGT) Stock Analysis: Biotechnology Innovator With 40% Upside Potential - DirectorsTalk Interviews
Quarterly Risk: What is Cogent Biosciences Incs 5 year growth outlookMarket Performance Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough - AOL.com
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million - AOL.com
Readystate Asset Management LP Takes $714,000 Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Piper Sandler raises Cogent stock price target on drug launch outlook By Investing.com - Investing.com Australia
Piper Sandler raises Cogent stock price target on drug launch outlook - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Cogent Biosciences (COGT) - The Globe and Mail
COGT Sees a Boost in Price Target and Maintained Overweight Rati - GuruFocus
Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib NDA Filings Earnings Update And New Shelf Registration - Sahm
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Decoding Cogent Biosciences Inc (COGT): A Strategic SWOT Insight - GuruFocus
Cogent Biosciences (NASDAQ:COGT) Progress Versus Market Expectations This Quarter - Kalkine Media
(COGT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Cogent Biosciences (COGT) Reports Strong Cash Position by Year-E - GuruFocus
Cogent Biosciences, Inc. SEC 10-K Report - TradingView
COGT Plans to Launch Bezuclastinib Following Key Regulatory Subm - GuruFocus
Cogent Biosciences (NASDAQ:COGT) Issues Earnings Results - MarketBeat
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
BRIEF-Cogent Biosciences Q4 Operating Expenses USD 99.493 Million - TradingView
Cogent Biosciences (COGT) to Release Quarterly Earnings on Tuesday - MarketBeat
Cogent Biosciences announces proposed concurrent public offerings - MSN
272,460 Shares in Cogent Biosciences, Inc. $COGT Acquired by Principal Financial Group Inc. - MarketBeat
How cyclical is Cogent Biosciences Inc.’s revenue streamEarnings Summary Report & Safe Swing Trade Setups - mfd.ru
Cogent Biosciences, Inc. (COGT) Stock Analysis: Exploring a Potential 43% Upside with Innovative Biotech Approaches - DirectorsTalk Interviews
What are Cogent Biosciences Inc.’s recent SEC filings showingMarket Performance Report & Risk Controlled Stock Pick Alerts - mfd.ru
Cogent Biosciences, Inc. $COGT Shares Bought by Candriam S.C.A. - MarketBeat
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting - Investing News Network
Support Test: Is Cogent Biosciences Inc forming a double bottomWatch List & Short-Term Trading Alerts - baoquankhu1.vn
(COGT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Federated Hermes Inc. Purchases 93,223 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Is FDA Breakthrough Status And Rapid Review For Bezuclastinib Reshaping The Case For Cogent Biosciences (COGT)? - Sahm
Assessing Cogent Biosciences (COGT) Valuation After FDA Breakthrough Therapy And Real Time Oncology Review News - Sahm
Commit To Buy Cogent Biosciences At $25, Earn 17.2% Using Options - Nasdaq
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):